174 related articles for article (PubMed ID: 16801939)
1. The changing pattern of management for hormone-refractory, metastatic prostate cancer.
James ND; Bloomfield D; Luscombe C
Prostate Cancer Prostatic Dis; 2006; 9(3):221-9. PubMed ID: 16801939
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic options for hormone-refractory prostate cancer in 2007.
Hadaschik BA; Gleave ME
Urol Oncol; 2007; 25(5):413-9. PubMed ID: 17826663
[TBL] [Abstract][Full Text] [Related]
3. Management of the spectrum of hormone refractory prostate cancer.
Clarke NW
Eur Urol; 2006 Sep; 50(3):428-38; discussion 438-9. PubMed ID: 16797118
[TBL] [Abstract][Full Text] [Related]
4. Chemotherapy for hormone-refractory prostate cancer.
Shelley M; Harrison C; Coles B; Staffurth J; Wilt TJ; Mason MD
Cochrane Database Syst Rev; 2006 Oct; (4):CD005247. PubMed ID: 17054249
[TBL] [Abstract][Full Text] [Related]
5. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
[TBL] [Abstract][Full Text] [Related]
6. Second-line treatment of metastatic prostate cancer. Prednisone and radiotherapy for symptom relief.
Prescrire Int; 2013 Mar; 22(136):74-8. PubMed ID: 23593699
[TBL] [Abstract][Full Text] [Related]
7. TRAPEZE: a randomised controlled trial of the clinical effectiveness and cost-effectiveness of chemotherapy with zoledronic acid, strontium-89, or both, in men with bony metastatic castration-refractory prostate cancer.
James N; Pirrie S; Pope A; Barton D; Andronis L; Goranitis I; Collins S; McLaren D; O'Sullivan J; Parker C; Porfiri E; Staffurth J; Stanley A; Wylie J; Beesley S; Birtle A; Brown J; Chakraborti P; Russell M; Billingham L
Health Technol Assess; 2016 Jul; 20(53):1-288. PubMed ID: 27434595
[TBL] [Abstract][Full Text] [Related]
8. [Treatment of hormone-resistant prostate cancer].
Lilleby W; Hernes E; Waehre H; Raabe N; Fosså SD
Tidsskr Nor Laegeforen; 2006 Nov; 126(21):2798-801. PubMed ID: 17086220
[TBL] [Abstract][Full Text] [Related]
9. Targeting Metastatic Hormone Sensitive Prostate Cancer: Chemohormonal Therapy and New Combinatorial Approaches.
Damodaran S; Lang JM; Jarrard DF
J Urol; 2019 May; 201(5):876-885. PubMed ID: 30747897
[TBL] [Abstract][Full Text] [Related]
10. [Systemic treatment of metastatic prostate cancer].
Wörmann B; Wolff JM
Urologe A; 2010 Feb; 49(2):221-7. PubMed ID: 20180063
[TBL] [Abstract][Full Text] [Related]
11. Combination of docetaxel, estramustine phosphate, and zoledronic acid in androgen-independent metastatic prostate cancer: efficacy, safety, and clinical benefit assessment.
Efstathiou E; Bozas G; Kostakopoulos A; Kastritis E; Deliveliotis C; Antoniou N; Skarlos D; Papadimitriou C; Dimopoulos MA; Bamias A
Urology; 2005 Jan; 65(1):126-30. PubMed ID: 15667877
[TBL] [Abstract][Full Text] [Related]
12. Current status of treatment for patients with metastatic prostate cancer.
Higano CS
Can J Urol; 2005 Jun; 12 Suppl 2():38-41. PubMed ID: 16018832
[TBL] [Abstract][Full Text] [Related]
13. A systematic review of the effectiveness of docetaxel and mitoxantrone for the treatment of metastatic hormone-refractory prostate cancer.
Collins R; Trowman R; Norman G; Light K; Birtle A; Fenwick E; Palmer S; Riemsma R
Br J Cancer; 2006 Aug; 95(4):457-62. PubMed ID: 16880788
[TBL] [Abstract][Full Text] [Related]
14. Treatment options in androgen-independent prostate cancer.
Lara PN; Meyers FJ
Cancer Invest; 1999; 17(2):137-44. PubMed ID: 10071598
[TBL] [Abstract][Full Text] [Related]
15. Treatment options in hormone-refractory metastatic prostate carcinoma.
Fusi A; Procopio G; Della Torre S; Ricotta R; Bianchini G; Salvioni R; Ferrari L; Martinetti A; Savelli G; Villa S; Bajetta E
Tumori; 2004; 90(6):535-46. PubMed ID: 15762353
[TBL] [Abstract][Full Text] [Related]
16. Overview of Systemic Therapy Augmenting Management of High-risk Localized Prostate Cancer.
Vicier C; Feng FY; Fizazi K
Eur Urol Focus; 2019 Mar; 5(2):168-170. PubMed ID: 30745118
[TBL] [Abstract][Full Text] [Related]
17. Controversies in chemotherapy of prostate cancer.
Heicappell R
Front Radiat Ther Oncol; 2002; 36():72-80. PubMed ID: 11842757
[No Abstract] [Full Text] [Related]
18. Chemotherapy in advanced androgen-independent prostate cancer 1990-1999: a decade of progress?
Culine S; Droz JP
Ann Oncol; 2000 Dec; 11(12):1523-30. PubMed ID: 11205458
[TBL] [Abstract][Full Text] [Related]
19. Advances in prostate cancer chemotherapy: a new era begins.
Pienta KJ; Smith DC
CA Cancer J Clin; 2005; 55(5):300-18; quiz 323-5. PubMed ID: 16166075
[TBL] [Abstract][Full Text] [Related]
20. NICE guidance on cabazitaxel for hormone-refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen.
Jilani A; George E; Adler AI
Lancet Oncol; 2012 Jun; 13(6):573-4. PubMed ID: 22833888
[No Abstract] [Full Text] [Related]
[Next] [New Search]
